BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15790508)

  • 1. Engineering of human complement component C3 for catalytic inhibition of complement.
    Kölln J; Bredehorst R; Spillner E
    Immunol Lett; 2005 Apr; 98(1):49-56. PubMed ID: 15790508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
    Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
    Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family.
    Low PJ; Ai R; Ogata RT
    J Immunol; 1999 Jun; 162(11):6580-8. PubMed ID: 10352274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third component of trout complement. cDNA cloning and conservation of functional sites.
    Lambris JD; Lao Z; Pang J; Alsenz J
    J Immunol; 1993 Dec; 151(11):6123-34. PubMed ID: 8245455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
    Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
    Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distal recognition site for classical pathway convertase located in the C345C/netrin module of complement component C5.
    Sandoval A; Ai R; Ostresh JM; Ogata RT
    J Immunol; 2000 Jul; 165(2):1066-73. PubMed ID: 10878385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary structure of cobra complement component C3.
    Fritzinger DC; Petrella EC; Connelly MB; Bredehorst R; Vogel CW
    J Immunol; 1992 Dec; 149(11):3554-62. PubMed ID: 1431125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus.
    Rehana S; Manjunatha Kini R
    Toxicon; 2007 Jul; 50(1):32-52. PubMed ID: 17412383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
    Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
    Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement inactivation by recombinant human C3 derivatives.
    Kölln J; Spillner E; Andrä J; Klensang K; Bredehorst R
    J Immunol; 2004 Nov; 173(9):5540-5. PubMed ID: 15494503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
    Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
    Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spermatogenic cells distal to the blood-testis barrier in rats lack C3 convertase regulators and may be at risk of complement-mediated injury.
    Mizuno M; Harris CL; Morgan BP
    J Reprod Immunol; 2006 Feb; 69(1):23-34. PubMed ID: 16380167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active sites in complement component C3 mapped by mutations at indels.
    Ogata RT; Ai R; Low PJ
    J Immunol; 1998 Nov; 161(9):4785-94. PubMed ID: 9794410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and function of recombinant cobra venom factor.
    Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
    J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of Cobra Venom Factor/human C3 chimeras transiently expressed in mammalian cells.
    Kölln J; Matzas M; Jänner N; Mix T; Klensang K; Bredehorst R; Spillner E
    Mol Immunol; 2004 May; 41(1):19-28. PubMed ID: 15140572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
    Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
    Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.